PRAS40 is an integral regulatory component of erythropoietin mTOR signaling and cytoprotection.
Emerging strategies that center upon the mammalian target of rapamycin (mTOR) signaling for neurodegenerative disorders may bring effective treatment for a number of difficult disease entities. Here we show that erythropoietin (EPO), a novel agent for nervous system disorders, prevents apoptotic SH-...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | article |
| Language: | EN |
| Published: |
Public Library of Science (PLoS)
2012
|
| Subjects: | |
| Online Access: | https://doaj.org/article/e4748a24e1de4cf9a68d9afe7be07a80 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|